Buscar
Mostrando ítems 41-50 de 54
Doenças desmielinizantes recorrentes na população pediátrica: estudo retrospectivo dos pacientes acompanhados no ambulatório de doenças desmielinizantes da Universidade Federal de São Paulo - Escola Paulista de Medicina
(Universidade Federal de São Paulo (UNIFESP), 2018-04-26)
Introdução: Esclerose múltipla (EM) e neuromielite óptica (NMO) são doenças
inflamatórias desmielinizantes do sistema nervoso central (SNC), que ocorrem com
maior frequência em adultos jovens, sendo raros os casos com ...
Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis
(Elsevier, 2020)
Background: : In relapsing -remitting multiple sclerosis (RRMS), no evidence of disease activity -3 (NEDA-3) is defined as the absence of: (1) relapses; (2) disability progression; (3) MRI activity (new/enlarged T2 lesions ...
Neuromyelitis Optica With Onset in Childhood and Adolescence
(Elsevier B.V., 2014-01-01)
BACKGROUND: Neuromyelitis optica with onset before the age of 18 years is a relatively rare, yet potentially devastating condition. the objective of the present study was to contribute to the study of early-onset neuromyelitis ...
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
(2022)
Background: Safety and effectiveness outcomes in Multiple Sclerosis (MS) patients receiving different disease- modifying therapies (DMT) and different types of vaccines against SARS-CoV-2 are limited. Growing evidence ...
Avaliação do efeito de derivados lipofílicos da genisteína na ativação de macrófagos in vitro e na modulação da resposta imune no modelo de EAE
(Universidade Federal de Juiz de Fora (UFJF)BrasilFaculdade de MedicinaPrograma de Pós-graduação em Saúde BrasileiraUFJF, 2017)
How Do We Manage And Treat A Patient With Multiple Sclerosis At Risk Of Tuberculosis?
(Expert Reviews Ltd., 2014)
Associations of Disease-Modifying Therapies with COVID-19 Severity in Multiple Sclerosis
(2021-11-09)
Background and ObjectivesPeople with multiple sclerosis MS are a vulnerable group for severe coronavirus disease 2019 COVID-19, particularly those taking immunosuppressive disease-modifying therapies DMTs. We examined the ...